📗 Cite This Artifact
Neurodegeneration-Focused Investment Funds
Overview
The neurodegenerative disease therapeutic space has attracted significant venture capital investment from specialized funds focused on brain health and neurology. These investors play a critical role in funding early-stage companies developing novel therapies for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
Major Neurodegeneration-Focused Investment Funds
Dementia Discovery Fund (DDF)
Overview: The Dementia Discovery Fund is a venture capital fund dedicated to investing in novel therapeutics for dementia and neurodegenerative diseases. Established in 2015, it brings together pharmaceutical companies, research institutions, and investors to accelerate the development of disease-modifying treatments.
Focus Areas:
- Alzheimer's disease and related dementias
- Novel therapeutic targets beyond amyloid and tau
- Biomarker development and patient stratification
- Disease-modifying therapies
Portfolio Companies:
- [Acumen Pharmaceuticals](https://acumenpharma.com) — Amyloid-beta targeting antibodies](/companies/acumen-pharmaceuticals)
- [ProMIS Neurosciences](https://promisneurosciences.com) — Amyloid-beta oligomer inhibitors](/companies/promis-neurosciences)
- [Neurocentrx](https://neurocentrx.com) — Novel mechanisms for neurodegeneration
SV Health Investors
...
Overview
The neurodegenerative disease therapeutic space has attracted significant venture capital investment from specialized funds focused on brain health and neurology. These investors play a critical role in funding early-stage companies developing novel therapies for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
Major Neurodegeneration-Focused Investment Funds
Dementia Discovery Fund (DDF)
Overview: The Dementia Discovery Fund is a venture capital fund dedicated to investing in novel therapeutics for dementia and neurodegenerative diseases. Established in 2015, it brings together pharmaceutical companies, research institutions, and investors to accelerate the development of disease-modifying treatments.
Focus Areas:
- Alzheimer's disease and related dementias
- Novel therapeutic targets beyond amyloid and tau
- Biomarker development and patient stratification
- Disease-modifying therapies
Portfolio Companies:
- [Acumen Pharmaceuticals](https://acumenpharma.com) — Amyloid-beta targeting antibodies](/companies/acumen-pharmaceuticals)
- [ProMIS Neurosciences](https://promisneurosciences.com) — Amyloid-beta oligomer inhibitors](/companies/promis-neurosciences)
- [Neurocentrx](https://neurocentrx.com) — Novel mechanisms for neurodegeneration
SV Health Investors
Overview: SV Health Investors is a healthcare-focused venture capital firm with a significant portfolio in neurology and neurodegeneration. The fund has been investing in the space for over two decades.
Focus Areas:
- Alzheimer's disease and Parkinson's disease
- Novel drug delivery technologies
- Biomarkers and diagnostic development
- Gene therapy for neurological disorders
Portfolio Companies:
- [Denali Therapeutics](https://denalitherapeutics.com) — LRRK2 and other neurodegeneration targets (IPO 2017)](/therapeutics)
- [Axial Therapeutics](https://axialtx.com) — Microbiome-based approaches for neurodegeneration](/therapeutics)
- [Ventus Therapeutics](https://ventustx.com) — Novel small molecule approaches
- Denali Therapeutics IPO (NASDAQ: DNLI)
- Multiple acquisitions by pharmaceutical partners
Third Rock Ventures
Overview: Third Rock Ventures is a leading biotech venture capital firm with a strong focus on neurology and neurodegenerative diseases. The fund takes an active role in company building and has launched multiple neurodegeneration-focused companies.
Focus Areas:
- Alzheimer's disease and Parkinson's disease
- Rare neurological diseases
- Novel modality development (gene therapy, RNA therapeutics)
- Neuroinflammation targeting
Portfolio Companies:
- [Prothelia](https://prothelia.com) — Novel therapies for neurodegenerative diseases](/companies/prothelia)
- [Karyopharm Therapeutics](https://karyopharm.com) — Novel mechanism approaches
- Multiple strategic partnerships with major pharma
Google Ventures (GV)
Overview: GV, the venture capital arm of Alphabet, has invested in multiple companies developing treatments for neurodegenerative diseases, focusing on innovative approaches and digital health solutions.
Focus Areas:
- Digital therapeutics and monitoring
- Novel drug delivery systems
- AI/ML-driven drug discovery
- Cell and gene therapy
Portfolio Companies:
- [Calico](https://calicolabs.com) — Longevity and age-related diseases (major investment)](/investment)
- [Unity Biotechnology](https://unitybiotechnology.com) — Senolytic therapeutics for age-related diseases
Andreessen Horowitz (a16z)
Overview: Andreessen Horowitz has expanded into biotech and healthcare investments, including companies focused on neurological diseases and brain health.
Focus Areas:
- Computational biology and AI-driven drug discovery
- Platform technologies
- Digital health and brain-computer interfaces
- Novel therapeutic modalities
Portfolio Companies:
- [BioAge Labs](https://bioagelabs.com) — Aging-focused therapeutics](/therapeutics)
- [Healx](https://healx.ai) — AI-driven rare disease drug discovery](/companies/healx)
- [Recursion Pharmaceuticals](https://recursionpharma.com) — AI-driven drug discovery (NASDAQ: RXRX)
- Recursion Pharmaceuticals IPO
- Multiple M&A transactions
ARCH Venture Partners
Overview: ARCH Venture Partners is one of the leading biotech venture capital firms, with extensive experience in founding and building successful neuroscience companies.
Focus Areas:
- Alzheimer's disease and Parkinson's disease
- Novel therapeutic modalities
- Platform technologies
- CNS drug delivery
Portfolio Companies:
- [Denali Therapeutics](https://denalitherapeutics.com) — Founded by ARCH (IPO 2017)](/therapeutics)
- [Celsius Therapeutics](https://celsiusrx.com) — Novel approaches for inflammatory diseases](/therapeutics)
- [Molecular Templates](https://moleculartemplates.com) — Novel ADC technologies
- Denali Therapeutics IPO (NASDAQ: DNLI)
- Multiple pharmaceutical partnerships
Versant Ventures
Overview: Versant Ventures is a healthcare-focused venture capital firm with a strong track record in neurology and neurodegeneration investments.
Focus Areas:
- Alzheimer's disease and Parkinson's disease
- Gene therapy and novel modalities
- Rare neurological diseases
- Regenerative medicine
Portfolio Companies:
- [BlueRock Therapeutics](https://bluerocktx.com) — Cell therapy (bought by Bayer)](/therapeutics)
- [CRISPR Therapeutics](https://crisprtx.com) — Gene editing (NASDAQ: CRSP)](/therapeutics)
- [MistyMount Pharmaceuticals](https://mistymount.com) — Neurodegeneration pipeline
- BlueRock Therapeutics acquisition by Bayer ($1B+)
- CRISPR Therapeutics IPO
Lightstone Ventures
Overview: Lightstone Ventures focuses on early-stage life science companies, with investments in multiple neurodegeneration-focused biotechs.
Focus Areas:
- Novel mechanisms for neurodegeneration
- CNS drug delivery
- Biomarker development
- Regenerative approaches
Portfolio Companies:
- [Alector](https://alector.com) — Immune-neurology approaches (NASDAQ: ALEC)
- [Tyra Biosciences](https://tyrabio.com) — Novel kinase inhibitors
- [Scribe Therapeutics](https://scribetx.com) — Gene editing technologies
- Alector IPO (NASDAQ: ALEC)
- Multiple strategic transactions
Investment Themes in Neurodegeneration
Emerging Focus Areas
The investment landscape in neurodegeneration has evolved significantly, with investors now focusing on:
Investment Trends
- Increasing Series A activity: More early-stage funding for novel mechanisms
- Cross-border investment: US and EU investors collaborating on global opportunities
- Academic spinouts: Increased investment in university-founded companies
- Strategic partnerships: Pharmaceutical companies increasingly partnering with VCs for deal flow
Key Considerations for Investors
Risk Factors
- Clinical trial complexity in neurodegeneration
- Patient recruitment challenges
- Regulatory pathway uncertainties
- Competitive landscape
- Reimbursement and pricing pressures
Opportunity Areas
- Unmet medical need remains very high
- Recent regulatory approvals validate the space
- Aging demographics drive market growth
- Novel mechanisms showing promise
- Combination of biomarkers and novel therapies
Related Pages
- [Investment Landscape: Neurodegeneration](/investment/investment-landscape-neurodegeneration)](/investment)
- [Alzheimer's Disease Investment](/investment/alzheimers)](/investment)
- [Parkinson's Disease Investment](/investment/parkinsons)](/investment)
- [ALS Investment](/investment/als)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | investment-neurodegeneration-investment-funds |
| kg_node_id | None |
| entity_type | investment |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-fec5930bd7e8 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'investment-neurodegeneration-investment-funds'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-investment-neurodegeneration-investment-funds?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Neurodegeneration-Focused Investment Funds](http://scidex.ai/artifact/wiki-investment-neurodegeneration-investment-funds)
http://scidex.ai/artifact/wiki-investment-neurodegeneration-investment-funds